- Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome.
- The company IPOd in August 2020, and shares have risen from $20, to $79.6 at the time of writing as enthusiasm for the sector rises.
- Besides oncology, Kymera is the only TPD developer targeting dermatology - a highly-lucrative space in which its drugs may hold a competitive advantage based on preclinical data readouts.
- Kymera has struck up partnerships with Sanofi and Vertex, which could be worth up to $3bn in milestones plus tiered royalties.
- Management is inexperienced, and the space is competitive, but if its drugs deliver in the clinic, shares will trade >$100 by YE, and market cap could be >$10bn by the time a first drug is approved, likely to be 2025, in my view.
For further details see:
Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting